^
Association details:
| Biomarker: | HER-2 exon 20 insertion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Advanced lung adenocarcinoma with coexistent HER2 mutation and amplification and response to afatinib: a case report
Published date:
02/23/2020
Excerpt:
A 64-year-old Chinese woman was diagnosed with advanced lung adenocarcinoma...She was determined as having insertion mutations in exon 20 of the HER2 gene (c.2326G > TTGT) by the amplification refractory mutation system (ARMS) and HER2 gene amplification (HER2/CEP17 ratio 2.6) by fluorescence in situ hybridization (FISH)...Thereafter, she was treated with afatinib as first-line therapy, to which she responded.
DOI:
10.21037/apm.2020.02.14
